智通财经APP讯,以岭药业(002603.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,该药物名称:“LB220-D08缓释片”。
LB220-D08为公司自主研发的全新小分子化学药物,是公司具有独立知识产权的1类化学新药。本品为靶向FactorB因子的补体抑制剂。通过靶向抑制B因子,本品可选择性抑制旁路途径,阻止C3转化酶的活化,从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC,C5b-9)的形成,并保持凝集素和经典途径信号通路的正常功能。
智通财经APP讯,以岭药业(002603.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,该药物名称:“LB220-D08缓释片”。
LB220-D08为公司自主研发的全新小分子化学药物,是公司具有独立知识产权的1类化学新药。本品为靶向FactorB因子的补体抑制剂。通过靶向抑制B因子,本品可选择性抑制旁路途径,阻止C3转化酶的活化,从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC,C5b-9)的形成,并保持凝集素和经典途径信号通路的正常功能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.